Recent performance snapshot for Jazz Pharmaceuticals (JAZZ)

With no single headline event driving attention today, Jazz Pharmaceuticals (JAZZ) is drawing interest for its recent trading pattern, including a 0.2% daily move and a roughly 6.8% gain over the past week.

The recent 6.8% 7 day share price return sits against a 90 day share price return of 25.8% and a 1 year total shareholder return of 39.6%, which suggests momentum has been building despite a small year to date share price decline.

If Jazz Pharmaceuticals has caught your eye, it can also be a good moment to scan other healthcare names using the healthcare stocks and see what else fits your criteria.

With Jazz trading around $171.16, a value score of 6 and some measures hinting at a possible discount to certain estimates, the key question for you is whether this is a genuine opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 19.6% Undervalued

The most followed narrative pegs Jazz Pharmaceuticals' fair value at US$213 per share, above the last close of US$171.16, framing the current debate around upside potential and the assumptions behind that gap.

Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver.

Curious what kind of revenue mix, margin profile, and future earnings multiple are baked into that higher fair value, and how much hinges on oncology execution and Ziihera's uptake over time?

Result: Fair Value of $213 (UNDERVALUED)

However, you still need to weigh patent expiries that could pressure the oxybate franchise, as well as the risk that newer oncology and sleep launches ramp more slowly than analysts expect.

Build Your Own Jazz Pharmaceuticals Narrative

If you see the numbers differently or prefer to stick with your own work, you can test your assumptions and build a full view in minutes: Do it your way.

A great starting point for your Jazz Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Jazz looks interesting, do not stop there. Casting a wider net with a few focused stock lists can surface ideas that fit your style even better.

• Focus on value by scanning these 866 undervalued stocks based on cash flows that may be pricing in more caution than their cash flows suggest.
• Ride big technology shifts by checking out these 24 AI penny stocks that are tied to artificial intelligence themes you want in your portfolio.
• Target income opportunities by reviewing these 12 dividend stocks with yields > 3% that combine yield with the potential for steadier total returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.